MAXCYTE INC

On March 10, 2025, the Board approved, at the recommendation of the Compensation Committee, and the Company entered into, an amendment and restatement to that certain Severance Agreement, dated March 27, 2023 (the “Initial CFO Severance Agreement”), of Douglas Swirsky, its Chief Financial Officer (the “The CFO Severance Agreement Amendment”). The CFO Severance Agreement Amendment revises the Initial CFO Severance Agreement to provide for: (i) acceleration of vesting of Mr. Swirsky’s issued and outstanding equity awards in the event of a Change of Control Event (as defined in the CFO Severance Agreement Amendment), subject to certain conditions in connection with performance-based awards and (ii) payment in twelve installments of a severance amount in the event of a Non-CoC Triggering Event (as defined in the CFO Severance Agreement Amendment). The CFO Severance Agreement Amendment further requires Mr. Swirsky to provide a customary release of claims against the Company related to any rights or obligations under the Initial CFO Severance Agreement.

The foregoing description of the CFO Severance Agreement Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the CFO Severance Agreement Amendment. The CFO Severance Agreement Amendment is attached hereto as Exhibit 10.18,and is incorporated herein by reference.